← Back to Search

Immunomodulator

Evorpacept for Cancer

Phase 1

Waitlist Available

Research Sponsored by ALX Oncology Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 28 days

Awards & highlights

Study Summary

This trial is testing a new drug, evorpacept, to see if it is effective in treating advanced solid tumors and lymphoma.

Who is the study for?

This trial is for people with advanced solid tumors or relapsed/refractory Non-Hodgkin's lymphoma without standard treatment options. Participants must be in good physical condition, have proper bone marrow, kidney and liver function, and not have received certain prior treatments like high-dose chemotherapy with stem cell rescue.Check my eligibility

What is being tested?

The study is testing Evorpacept (ALX148) combined with other cancer drugs like Pembrolizumab and Trastuzumab to find the safest dose that works. It's a phase 1 trial which means it's early in the testing process and focuses on safety.See study design

What are the potential side effects?

Potential side effects may include reactions at the injection site, fatigue, nausea, lowered blood counts leading to increased infection risk or bleeding problems. Since this is an early-phase trial, there might be unknown side effects as well.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 28 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 28 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Dose-limiting toxicities (Number of participants with a DLT)

Trial Design

6Treatment groups

Experimental Treatment

Group I: Evorpacept (ALX148) + Trastuzumab + Ramucirumab + PaclitaxelExperimental Treatment3 Interventions

The Part 2 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with trastuzumab + ramucirumab + paclitaxel infusions.

Group II: Evorpacept (ALX148) + TrastuzumabExperimental Treatment2 Interventions

The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with trastuzumab infusions.

Group III: Evorpacept (ALX148) + RituximabExperimental Treatment2 Interventions

The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with rituximab infusions.

Group IV: Evorpacept (ALX148) + Pembrolizumab + 5FU + PlatinumExperimental Treatment3 Interventions

The Part 2 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with pembrolizumab + 5FU + platinum infusions.

Group V: Evorpacept (ALX148) + PembrolizumabExperimental Treatment2 Interventions

The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with pembrolizumab infusions.

Group VI: Evorpacept (ALX148)Experimental Treatment1 Intervention

The Part 1 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Pembrolizumab

2017

Completed Phase 2

~2010

Rituximab

1999

Completed Phase 4

~1880

Trastuzumab

2014

Completed Phase 4

~5190

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

ALX Oncology Inc.Lead Sponsor

8 Previous Clinical Trials

1,166 Total Patients Enrolled

Media Library

Evorpacept (ALX148) (Immunomodulator) Clinical Trial Eligibility Overview. Trial Name: NCT03013218 — Phase 1

Non-Hodgkin's Lymphoma Research Study Groups: Evorpacept (ALX148), Evorpacept (ALX148) + Pembrolizumab, Evorpacept (ALX148) + Rituximab, Evorpacept (ALX148) + Pembrolizumab + 5FU + Platinum, Evorpacept (ALX148) + Trastuzumab + Ramucirumab + Paclitaxel, Evorpacept (ALX148) + Trastuzumab

Non-Hodgkin's Lymphoma Clinical Trial 2023: Evorpacept (ALX148) Highlights & Side Effects. Trial Name: NCT03013218 — Phase 1

Evorpacept (ALX148) (Immunomodulator) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03013218 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any availabilities for participants to join this trial?

"According to the clinical data hosted on ClinicalTrials.gov, this particular trial is no longer enrolling patients as it was last modified in July 2022. However, there are 5102 other studies that currently require participants."

Answered by AI

What medical conditions are addressed by Evorpacept (ALX148)?

"Patients diagnosed with malignant esophageal neoplasms, Hodgkin's disease, and other illnesses can benefit from the use of Evorpacept (ALX148)."

Answered by AI

Could you please provide an overview of all the research initiatives in which Evorpacept (ALX148) has been employed?

"The origin of Evorpacept (ALX148) research can be traced back to 1993 at the National Institutes of Health Clinical Center in Rockville Pike. Since that time, 3241 studies have been conducted with 2667 currently active trials being administered predominantly from Denver, Colorado."

Answered by AI

To what degree could Evorpacept (ALX148) be detrimental to those who take it?

"Evorpacept (ALX148) has yet to be evaluated in any long-term studies, leading our team at Power to give it a safety rating of 1 on the scale from 1 to 3."

Answered by AI

Are there any outposts throughout the state where this trial is being administered?

"This trial is taking place at 6 different medical sites, which are based in Denver, Grand Rapids and New Haven, among other cities. To make participation easier on the patient, it is advised that they pick a site located nearest them to reduce commuting time."

Answered by AI

How many individuals have been enlisted to participate in this investigation?

"This clinical trial is now closed and no longer recruiting participants. It was posted on February 3rd, 2017 and the last update occured July 20th 2022. Nevertheless, there are numerous other studies currently enrolling with 2435 looking for metastatic cancer patients and 2667 searching for Evorpacept (ALX148) candidates."

Answered by AI

Recent research and studies

The Lancet OncologyJournal

Evorpacept Alone and in Combination with Pembrolizumab or Trastuzumab in Patients with Advanced Solid Tumours (ASPEN-01): A First-in-human, Open-label, Multicentre, Phase 1 Dose-escalation and Dose-expansion Study

Lakhani, Nehal J, Laura Q M Chow, Justin F Gainor, Patricia LoRusso, Keun-Wook Lee, Hyun Cheol Chung, Jeeyun Lee, et al.. 2021. “Evorpacept Alone and in Combination with Pembrolizumab or Trastuzumab in Patients with Advanced Solid Tumours (ASPEN-01): A First-in-human, Open-label, Multicentre, Phase 1 Dose-escalation and Dose-expansion Study”. The Lancet Oncology. Elsevier BV. doi:10.1016/s1470-2045(21)00584-2.

The Lancet OncologyJournal

clinicaltrials.govStudy

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

2017. "A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03013218.